Loading clinical trials...
Loading clinical trials...
A Prospective, Multi-centre, Randomized, Double-blind, Sham-controlled, Parallel-group, Group-sequential Study to Investigate Safety and Effectiveness of the Rehaler Partial Rebreathing Device, in Adults Suffering From Migraine With Aura
Conditions
Interventions
Partial Rebreathing Device
Sham breathing device
Locations
15
United States
Stanford University - Stanford Headache Clinic
Palo Alto, California, United States
Profound Research-Southern California Neurology Consultants
Pasadena, California, United States
Artemis Institute for Clinical Research
Riverside, California, United States
Yale University
New Haven, Connecticut, United States
MedStar Health Research Institute
Washington D.C., District of Columbia, United States
University of Miami
Miami, Florida, United States
Start Date
August 8, 2023
Primary Completion Date
October 30, 2024
Completion Date
October 30, 2024
Last Updated
March 25, 2025
NCT04715685
NCT07021859
NCT06617832
NCT05903040
NCT07342296
NCT04940390
Lead Sponsor
Rehaler
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions